Peptide
Peptide receptors, in general, are members of the large family of G-protein coupled receptors (GPCRs). Their endogenous ligands are neuropeptides and proteins of various kinds, such as chemokine (subfamily A1), vasopressin (subfamily A6), neurokinin (subfamily A9), and thrombin (subfamily A15). The diversity of endogenous ligands implies the wide range of biological processes they are involved in: include learning, memory, response to stress, pain, addiction, feeding behavior, sexual behavior, reproduction, the immune response, thermal control, kidney function, cardiovascular function (including blood pressure and heart rate) and many others[1]. The discovery that peptide receptors (somatostatin (subfamily A4) in particular) are over-expressed in most human neuroendocrine tumors has focused the recent interest in peptide receptors as potential targets for the treatment of cancers[2].
[1] Designing peptide receptor agonists and antagonists. V.J. Hruby. Nature Reviews Drug Discovery 2002, 1, 847-858.
[2] Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. Reubi J.C. J. Nucl. Med. 1995, 36,1825–1835.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 3890 | (R)-(-)-PD123319 ditrifluoroacetate (Optically pure) | Opposite enantiomer of PD123319 ditrifluoroacetate | €140.00 | |
| 3435 | (S)-VU0637120 | First-in-class, selective neuropeptide Y4 receptor allosteric antagonist | €120.00 | |
| 1179 | A1B1 hydrochloride | CCR1 antagonist | €125.00 | |
| 2898 | AC 264613 | Potent, selective, and metabolically stable PAR2 agonist | €95.00 | |
| 2388 | Adomeglivant | Potent, selective, orally administered, and competitive human glucagon receptor (GR) antagonist | €95.00 | |
| 1648 | Ambrisentan | Endothelin-A (ETA) antagonist | €70.00 | |
| 1738 | AMD 3100 | CXCR4 antagonist | €90.00 | |
| 1930 | AMD 3465 hexahydrobromide | Potent and selective CXCR4 antagonist | €85.00 | |
| 1486 | Aprepitant | Substance P antagonist (SPA); NK1 inhibitor | €80.00 | |
| 4058 | Atrasentan | Highly potent, selective, and orally active endothelin-A (ETA) antagonist | €130.00 | |
| 3386 | AVE0991 | Selective and orally active Mas receptor agonist | €150.00 | |
| 2340 | AZ-GHS-22 | Orally available Ghrelin receptor (GHS-R1a) inverse agonist | €160.00 | |
| 2842 | AZD2098 | Potent, selective and bioavailable CCR4 receptor antagonist | €125.00 | |
| 2255 | AZD8797 | Potent and selective antagonist of the Fractalkine receptor (FKN or CX3CR1) | €120.00 | |
| 3363 | Azilsartan | Potent AT1 antagonist | €60.00 | |
| 4104 | BAY 2686013 hydrochloride | Potent and selective allosteric hPAC1 receptor antagonist | €120.00 | |
| 2259 | BETP | Positive allosteric modulator (PAM) at the GLP-1 receptor | €105.00 | |
| 1969 | Buloxibutid | First non-peptide selective AT2 receptor agonist | Inquire | |
| 2082 | BX 471 | Selective CCR1 receptor antagonist | €105.00 | |
| 3104 | Candesartan cilexetil | Potent and highly specific AT2 receptor antagonist | €50.00 | |
| 1901 | Casopitant mesylate | NK1 antagonist | €125.00 | |
| 2665 | Cenicriviroc | Oral CCR5-antagonist for treatment of HIV infection | €160.00 | |
| 2147 | CpdD hydrochloride | Ghrelin receptor (GhrR aka GHSR-1a) antagonist | €135.00 | |
| 1800 | CXCR3 Antagonist 6c | CXCR3 antagonist | €135.00 | |
| 2895 | D3-βArr | Positive allosteric modulator (PAM) of TSH receptor | €105.00 | |
| 1975 | Dilept | Neurotensin and dopamine receptor antagonist | €90.00 | |
| 2030 | E 5555 hydrobromide | Potent and orally active PAR1 antagonist | €115.00 | |
| 2012 | EMPA | Orexin type 2 (OX2) receptor antagonist | €135.00 | |
| 2146 | Fedovapagon | Selective vasopressin V2 receptor agonist | €140.00 | |
| 3403 | Fezolinetant | Orally bioavailable NK3 antagonist | €140.00 | |